Breaking News

ADP Research Institute Says U.S. Added 213,000 Jobs in September
Tweet TWEET

Clinical Study Updates, Trial Enrollments, NDA Submissions, Partnerships, and Formation of New Subsidiaries - Research Report on

Clinical Study Updates, Trial Enrollments, NDA Submissions, Partnerships, and
Formation of New Subsidiaries - Research Report on BioMarin, Alnylam, Vertex,
                            Illumina, and Intrexon

PR Newswire

NEW YORK, October 7, 2013

NEW YORK, October 7, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting BioMarin
Pharmaceutical Inc. (NASDAQ: BMRN), Alnylam Pharmaceuticals, Inc. (NASDAQ:
ALNY), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Illumina, Inc.
(NASDAQ: ILMN), and Intrexon Corporation (NYSE: XON). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

BioMarin Pharmaceutical Inc. Research Report

On September 29, 2013, BioMarin Pharmaceutical Inc. (BioMarin) provided an
update on the ongoing Phase 1/2 study for its poly ADP-ribose polymerase
(PARP) inhibitor, BMN 673, for the treatment of solid tumors. According to the
presented data, the confirmed RECIST response rate among 14 gBRCA breast
cancer patients treated at the dose of 1mg/day selected for the Phase 3 study
was 50%, with seven confirmed objective responses - one complete and six
partial. Further the data revealed that there were five patients with stable
disease lasting at least 24 weeks for an overall clinical benefit response
rate at this dose of 86%. In addition, the Company informed that the BMN 673
was generally well-tolerated. Hank Fuchs, M.D., Chief Medical Officer of
BioMarin, said, "With the imminent initiation of the Phase 3 program in
germline BRCA mutation metastatic breast cancer, we are closer to
understanding the significant role BMN 673 may play for patients suffering
metastatic breast cancer." The Full Research Report on BioMarin Pharmaceutical
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9b6c_BMRN]

--

Alnylam Pharmaceuticals, Inc. Research Report

On September 30, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that
it has completed enrollment in its Phase II trial with ALN-TTR02, an RNAi
therapeutic targeting the transthyretin (TTR) gene for the treatment of
TTR-mediated amyloidosis (ATTR). According to the recent interim result,
ALN-TTR02 has achieved up to 93% knockdown of TTR - the disease-causing
protein in ATTR. In addition, the Company also announced that its open-label
extension (OLE) study with ALN-TTR02 is open for enrollment. Akshay Vaishnaw,
M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam,
said "Our ATTR program is the lead effort in our 'Alnylam 5x15' product
development and commercialization strategy, which is focused on advancing RNAi
therapeutics toward genetically defined targets for the treatment of diseases
with high unmet medical need. We are very encouraged with the clinical
activity, safety, and tolerability seen to date with ALN-TTR02 in our Phase II
multi-dose study performed in ATTR patients, and look forward to sharing
further data at the upcoming ISFAP meeting in November." The Full Research
Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/5b29_ALNY]

--

Vertex Pharmaceuticals Incorporated Research Report

On September 30, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced
that it has submitted a supplemental New Drug Application (sNDA) to the FDA
for the approval of KALYDECO™ (ivacaftor) monotherapy for people with cystic
fibrosis (CF), six years old and above, who have at least one non-G551D gating
mutation in the CF transmembrane conductance regulator (CFTR) gene. According
to the Company, currently, KALYDECO is approved for people with CF, six years
old and above, who have at least one copy of the G551D mutation. The Company
stated that the sNDA submission is based on previously announced data from a
Phase 3 study of ivacaftor monotherapy that showed statistically significant
improvements in lung function. Vertex also informed that it plans to submit a
Marketing Authorization Application (MAA) variation in Europe in October 2013
for people with CF ages six and above, who have at least one non-G551D gating
mutation. The Full Research Report on Vertex Pharmaceuticals Incorporated -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e696_VRTX]

--

Illumina, Inc. Research Report

On September 25, 2013, Illumina, Inc. (Illumina) announced that it has entered
into a partnership with Global Genomics Group (G3) to investigate novel
biomarkers and biological pathways involved in the development and diagnosis
of cardiovascular diseases. According to the agreement, Illumina will conduct
whole genome sequencing (WGS) in the GLOBAL (Genetic Loci and the Burden of
Atherosclerotic Lesions) clinical study. Szilard Voros, M.D., CEO and
Co-Founder of G3, said, "This is the first study of its kind, analyzing
trillions of data points from 7,000 patients, designed to investigate the
biological basis behind the complex processes responsible for
atherosclerosis., To date we have collected more than 2,200 samples, and we
anticipate completing enrollment by summer of 2014." The Full Research Report
on Illumina, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/3cf2_ILMN]

--

Intrexon Corporation Research Report

On October 2, 2013, Intrexon Corporation (Intrexon) announced the creation of
a new Living Arts subsidiary called Biological & Popular Culture, Inc.
(BioPop). The Company said that BioPop's team of innovative scientists and
creative designers, enabled by the synthetic biology engineering technology of
Intrexon, aims to create new bio-diverse products like those found in nature.
Andy Bass, CEO of BioPop said, "BioPop aims to evolve the traditional
biotechnology industry paradigm that focuses on healthcare and therapeutics.
The consumer market is large with diverse interests that will play a vibrant
role in biotech's future." Randal J. Kirk, Chairman and CEO of Intrexon added,
"While Intrexon continues its work to provide solutions to important problems
in Health, Food, Energy and Environment, we created, in partnership with Andy
Bass and his team, a separate company to focus on groundbreaking consumer
products rooted in synthetic biology. Initial applications will focus on
decorative and fine arts - even toys, both of which represent virtually
unlimited potential." The Full Research Report on Intrexon Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/cb5c_XON]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsCorner.com



SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.